Table III.

Foxp3 gene expression relative to β-actin in CD4+ cells from patients treated at 3 mg/kg anti-CTLA-4 Aba

PatientPretreatmentAfter 3 mg/kg
16.80 ± 0.266.40 ± 0.01
24.10 ± 0.275.56 ± 0.02
35.08 ± 4.5113.90 ± 0.90
415.33 ± 0.4117.29 ± 0.96
50.16 ± 0.010.32 ± 0.01
60.10 ± 0.000.22 ± 0.01
70.17 ± 0.010.23 ± 0.01
80.08 ± 0.010.17 ± 0.00
90.17 ± 0.010.27 ± 0.00
100.26 ± 0.020.25 ± 0.00
  • a CD4+ lymphocytes were purified from patients 1–10 before and after treatment with anti-CTLA-4 Ab. Patients 1–4 were treated with Ab alone, and patients 5–10 were treated with Ab plus peptide vaccine in two separate experiments. Foxp3 gene expression relative to β-actin was determined pretreatment and after receiving at least one dose at 3.0 mg/kg anti-CTLA-4 Ab.